RDY vs. TECH: Dr. Reddy's Laboratories vs. Bio-Techne Stock Comparison

Company Profile

Dr. Reddy's Laboratories (RDY) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RDY is classified in Pharmaceuticals while TECH is classified in Life Sciences Tools & Services.

Bio-Techne (TECH) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Dr. Reddy's Laboratories (RDY) at 7.34% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Dr. Reddy's Laboratories (RDY) at 8.49% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Dr. Reddy's Laboratories (RDY) at 14.73% and Bio-Techne (TECH) at 12.21% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

Profitability Metrics

Growth

Both Dr. Reddy's Laboratories (RDY) at 3.19% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while Dr. Reddy's Laboratories (RDY) at -24.14% is closer to the peer norm — faster per-share earnings growth for TECH.

Growth Metrics

Financial Strength

Both Dr. Reddy's Laboratories (RDY) at 1.93 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Dr. Reddy's Laboratories (RDY) at 0.19 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Both Dr. Reddy's Laboratories (RDY) at 55.06% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Dr. Reddy's Laboratories (RDY) at 22.72% and Bio-Techne (TECH) at 27.59% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Dr. Reddy's Laboratories (RDY) at 41.42 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Bio-Techne (TECH) at 9.31 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

Bio-Techne (TECH) at 5.28 sits near its industry’s typical P/B ratio, while Dr. Reddy's Laboratories (RDY) at 18.16 prices above its benchmark range — RDY looks rich relative to book.

Valuation Metrics